ERBB2 and breast cancer: Inhibition of PI3K leads to enhanced HER2 signalling in HER2-overexpressing breast cancer cells, suggesting that inhibitors targeting this pathway may act synergistically with trastuzumab in cells demonstrating resistance [105].